Eli Lilly and Company - Episode 33 - Sep 9, 2025

Eli Lilly (LLY) is a 150-year-old pharmaceutical giant that's suddenly acting like a Silicon Valley startup, with billion-dollar AI platforms and next-generation gene therapy deals—and the market is buying the story hook, line, and sinker. While bullish options traders are piling in and short-sellers are nowhere to be found, a deep dive into the numbers reveals a massive red flag: a valuation disconnect that suggests the stock is either a screaming buy or dangerously overhyped. With the price chart coiling like a spring for a major move, we dissect the fierce battle between an unstoppable narrative and the cautionary numbers. Tune in to find out if Eli Lilly is about to launch into the stratosphere or if its incredible story is about to collide with financial reality.

There are no comments yet.

Please log in to write the first comment.